Randomized Trial of Vaccines for Zaire Ebola Virus Disease

Mark Kieh, Laura Richert, Abdoul Habib Béavogui, Birgit Grund, Bailah Leigh, Éric D’Ortenzio, Seydou Doumbia, Edouard Lhomme, Samba O. Sow, Renaud Vatrinet

Type: Article

Publication Date: 2022-12-14

Citations: 51

DOI: https://doi.org/10.1056/nejmoa2200072

View Publication

Download PDF

Abstract

Questions remain concerning the rapidity of immune responses and the durability and safety of vaccines used to prevent Zaire Ebola virus disease.

Locations

HAL (Le Centre pour la Communication Scientifique Directe) - View
LSHTM Research Online (London School of Hygiene and Tropical Medicine) - View - PDF
PubMed - View
New England Journal of Medicine - View - PDF

Similar Works

Action	Title	Year	Authors
+ PDF Chat	Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study	2017	D. Gray Heppner Tracy Kemp Brian K. Martin W. Jay Ramsey Richard Nichols Emily J. Dasen Charles J. Link Rituparna Das Zhi Jin Xu Eric Sheldon
+ PDF Chat	Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults	2017	Scott A. Halperin José Ramón Arribas Richard Rupp Charles P. Andrews Laurence Chu Rituparna Das Jakub K. Simon Matthew T. Onorato Kenneth Liu Jason Martin
+	Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases	2024	Aurélie Wiedemann Édouard Lhomme Mélanie Huchon Emile Foucat Marion Bérerd-Camara Lydia Guillaumat Marcel Yaradouno Jacqueline Tambalou Cécile Rodrigues Alexandre Lima de Araújo Ribeiro
+ PDF Chat	A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks	2016	Georgi Shukarev Benoît Callendret Kerstin Lühn Macaya Douoguih
+ PDF Chat	Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials	2022	Jakub K. Simon Stephen B. Kennedy Barbara E. Mahon Sheri Dubey Rebecca J. Grant-Klein Ken Liu Jonathan Hartzel Beth-Ann Coller Carolee Welebob Mary E. Hanson
+	Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?	2018	Angela Huttner Claire‐Anne Siegrist
+	Vaccine development for emerging virulent infectious diseases	2017	Joel N. Maslow
+ PDF Chat	Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability	2023	Angela Huttner Sélidji Todagbé Agnandji Olivier Engler Jay W. Hooper Steve Kwilas Keersten M. Ricks Tamara L. Clements Hulda R. Jónsdóttir Sravya Sowdamini Nakka Sylvia Rothenberger
+	Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study	2024	Sophie Meakin Justus Nsio Anton Camacho Richard Kitenge Rebecca M. Coulborn Etienne Gignoux John Johnson Esther Sterk Elisabeth Mukamba Musenga Stéphane Hans Bateyi Mustafa
+	rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)	2024	Conall Watson Pierre‐Stéphane Gsell Yper Hall Anton Camacho Ximena Riveros Godwin Enwere Andrea Vicari Séverine Danmadji Nadlaou Alhassane Touré Ismaila M. Sani
+ PDF Chat	Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study	2024	Adeep Puri Andrew J. Pollard Catherine Schmidt‐Mutter Fabrice Lainé George PrayGod Hannah Kibuuka Houreratou Barry Jean‐François Nicolas Jean‐Daniel Lelièvre Sodiomon B. Sirima
+	Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity	2021	Amanda N. Pinski Ilhem Messaoudi
+ PDF Chat	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial	2020	Kathryn E. Stephenson Chen Tan Stephen R. Walsh Andrew J. Hale Jessica L. Ansel Diane G. Kanjilal Kate Jaegle Lauren Peter Erica N. Borducchi Joseph P. Nkolola
+ PDF Chat	Vaccines against Ebola virus	2017	Navin Venkatraman Daniel Silman Pedro M. Folegatti Adrian V. S. Hill
+	Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People With and Without Human Immunodeficiency Virus: A Randomized Clinical Trial	2021	Julie A. Ake Kristopher Paolino Jack Hutter Susan Cicatelli Leigh Anne Eller Michael A. Eller Margaret C. Costanzo Dominic Paquin‐Proulx Merlin L. Robb C. Lang Tran
+ PDF Chat	Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review	2019	Lindi Mathebula Duduzile Ndwandwe Elizabeth Pienaar Charles Shey Wiysonge
+ PDF Chat	To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity	2020	Amanda N. Pinski Ilhem Messaoudi
+ PDF Chat	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study	2018	Angela Huttner Sélidji Todagbé Agnandji Christophe Combescure José F. Fernandes Emmanuel B. Bache Lumeka Kabwende Francis M. Ndungu Jessica S. Brosnahan Thomas P. Monath Barbara Lemaître
+	Prior vaccination with recombinant Vesicular Stomatitis Virus – Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection	2020	Kasereka Masumbuko Claude Austin Ericson Andrea L. Conroy Tumba Lukaba Ombeni Didier Mwesha Michael Hawkes
+ PDF Chat	Safety and immunogenicity of Zika virus vaccine: A systematic review of clinical trials	2022	Mahmuda Yeasmin Md. Maruf Ahmed Molla H. M. Abdullah Al Masud KM Saif‐Ur‐Rahman

Works That Cite This (11)

Action	Title	Year	Authors
+ PDF Chat	Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study	2024	Adeep Puri Andrew J. Pollard Catherine Schmidt‐Mutter Fabrice Lainé George PrayGod Hannah Kibuuka Houreratou Barry Jean‐François Nicolas Jean‐Daniel Lelièvre Sodiomon B. Sirima
+ PDF Chat	Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans	2023	Chelsea McLean Karin Dijkman Auguste Gaddah Babajide Keshinro Michael Katwere Macaya Douoguih Cynthia Robinson Laura Solforosi Dominika N. Czapska-Casey Liesbeth Dekking
+	Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases	2024	Aurélie Wiedemann Édouard Lhomme Mélanie Huchon Emile Foucat Marion Bérerd-Camara Lydia Guillaumat Marcel Yaradouno Jacqueline Tambalou Cécile Rodrigues Alexandre Lima de Araújo Ribeiro
+	Urgent considerations for booster vaccination strategies against Ebola virus disease	2024	Wim Adriaensen Selien Oostvogels Yves Lévy Bailah Leigh Hugo Kavunga‐Membo Deborah Watson-Jones
+ PDF Chat	A Glass-Half-Full Perspective on Negative Data in Ebolavirus Vaccine Studies	2024	Abhishek N. Prasad Thomas W. Geisbert
+	rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)	2024	Conall Watson Pierre‐Stéphane Gsell Yper Hall Anton Camacho Ximena Riveros Godwin Enwere Andrea Vicari Séverine Danmadji Nadlaou Alhassane Touré Ismaila M. Sani
+ PDF Chat	Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions1	2024	Linda Bus-Jacobs Rute Lau Marjolein Soethoudt Lisa Gebbia Edwin Janssens Tjeerd Hermans
+	Ebola	2021	Heinz-J. Schmitt Khrystyna Hrynkevych
+ PDF Chat	Recent advances in the treatment of Ebola disease: A brief overview	2024	L’Emir Wassim El Ayoubi Omar Mahmoud Johnny Zakhour Souha S. Kanj
+	Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis	2024	Elin Hoffmann Dahl Placide Mbala Sylvain Juchet Abdoulaye Touré Alice Montoyo Béatrice Serra Richard Kojan Éric D’Ortenzio Bjørn Blomberg Marie Jaspard

Works Cited by This (2)

Action	Title	Year	Authors
+ PDF Chat	The cost of an Ebola case	2015	Sarah M. Bartsch Katrin M. Gorham Bruce Y. Lee
+ PDF Chat	Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study	2017	D. Gray Heppner Tracy Kemp Brian K. Martin W. Jay Ramsey Richard Nichols Emily J. Dasen Charles J. Link Rituparna Das Zhi Jin Xu Eric Sheldon